2021
Opioid Prescribing and Use Among Cancer Survivors: A Mapping Review of Observational and Intervention Studies
Check DK, Avecilla R, Mills C, Dinan MA, Kamal AH, Murphy B, Rezk S, Winn A, Oeffinger K. Opioid Prescribing and Use Among Cancer Survivors: A Mapping Review of Observational and Intervention Studies. Journal Of Pain And Symptom Management 2021, 63: e397-e417. PMID: 34748896, DOI: 10.1016/j.jpainsymman.2021.10.015.Peer-Reviewed Original ResearchConceptsOpioid useOpioid prescribingCancer survivorsHigh-risk opioid prescribingLong-term opioid useEvidence synthesisContinued opioid useLate opioid usePersistent opioid useProlonged opioid useChronic opioid useUse of opioidsHigh-risk medicationsOpioid use outcomesFull-text reviewTitles/abstractsOpioid misuseChronic useInclusion criteriaExclusion criteriaIntervention studiesInterventional researchPrescribingProlonged useStudy designReal-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States
Wilson LE, Spees L, Pritchard J, Greiner MA, Scales CD, Baggett CD, Kaye D, George DJ, Zhang T, Wheeler SB, Dinan MA. Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States. Kidney Cancer 2021, 5: 115-127. PMID: 34632169, PMCID: PMC8474520, DOI: 10.3233/kca-210119.Peer-Reviewed Original ResearchOral anticancer agentsMetastatic RCCPatient characteristicsMetastatic renal cell carcinomaPocket costsFirst oral therapySEER-Medicare analysisRepresentative patient populationRenal cell carcinomaAnticancer agentsPrescription drug coverageRace/ethnicityMRCC diagnosisMost patientsOral therapyUnmarried patientsCell carcinomaPatient populationAdvanced ageInclusion criteriaPatientsDrug coverageAge 65Medicare Part D prescription drug coverageSocioeconomic disparities
2020
Disparities in utilization of oral anticancer agents and related costs in elderly patients with metastatic renal cell carcinoma in the United States.
Wilson L, Spees L, Pritchard J, Greiner M, Scales C, Baggett C, Kaye D, George D, Zhang T, Wheeler S, Dinan M. Disparities in utilization of oral anticancer agents and related costs in elderly patients with metastatic renal cell carcinoma in the United States. Journal Of Clinical Oncology 2020, 38: 106-106. DOI: 10.1200/jco.2020.38.29_suppl.106.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsRenal cell carcinomaPatient characteristicsCell carcinomaManagement of mRCCSEER-Medicare patientsMultivariable-adjusted modelsMajority of patientsPatient-level characteristicsAnticancer agentsMedicare Part D benefitPart D benefitSurvival persistCertain comorbiditiesElderly patientsMultivariable adjustmentMarried patientsMetastatic diagnosisRace/ethnicity categoriesAdvanced ageInclusion criteriaHispanic ethnicityPatientsPocket spending
2013
Diagnosis Change in Voice‐Disordered Patients Evaluated by Primary Care and/or Otolaryngology: A Longitudinal Study
Cohen SM, Dinan MA, Roy N, Kim J, Courey M. Diagnosis Change in Voice‐Disordered Patients Evaluated by Primary Care and/or Otolaryngology: A Longitudinal Study. Otolaryngology 2013, 150: 95-102. PMID: 24264568, DOI: 10.1177/0194599813512982.Peer-Reviewed Original ResearchConceptsPrimary care physiciansOtolaryngology groupLaryngeal diagnosisInitial diagnosisClinical Modification codesHealth care utilizationVoice disordersLaryngeal cancer diagnosisNonspecific dysphoniaOutpatient visitsAcute laryngitisCare physiciansCare utilizationNinth RevisionPrimary careDifferential diagnosisRetrospective analysisAppropriate treatmentInclusion criteriaDiagnosis changeInternational ClassificationPatientsAccurate diagnosisLaryngeal disordersStudy designRisk of Acute Thromboembolic Events With Oral Contraceptive Use
Urrutia R, Coeytaux RR, McBroom AJ, Gierisch JM, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, Hasselblad V, Sanders GD, Myers ER. Risk of Acute Thromboembolic Events With Oral Contraceptive Use. Obstetrics And Gynecology 2013, 122: 380-389. PMID: 23969809, DOI: 10.1097/aog.0b013e3182994c43.Peer-Reviewed Original ResearchConceptsOral contraceptive pillsVenous thromboembolismMyocardial infarctionIschemic strokeHemorrhagic strokeOdds ratioCombined oral contraceptive pillAcute thromboembolic eventsOral contraceptive useRandomized clinical trialsSummary odds ratiosThromboembolic eventsCochrane DatabaseContraceptive pillsOCP useOCP usersClinical trialsSTUDY SELECTIONInclusion criteriaContraceptive useThromboembolismDiscordant decisionsSystematic reviewStrokeTeam reviewOral Contraceptive Pills as Primary Prevention for Ovarian Cancer
Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral Contraceptive Pills as Primary Prevention for Ovarian Cancer. Obstetrics And Gynecology 2013, 122: 139-147. PMID: 23743450, DOI: 10.1097/aog.0b013e318291c235.Peer-Reviewed Original ResearchConceptsOral contraceptive pillsUse of OCPOvarian cancer incidenceOCP useContraceptive pillsCancer incidenceOvarian cancerDuration-dependent reductionDuration-response relationshipOvarian cancer riskDuration of useCohort studyCochrane DatabasePrimary preventionSTUDY SELECTIONInclusion criteriaCancer riskDiscordant decisionsGeneral populationPrimary analysisSystematic reviewTeam reviewIncidenceSignificant reductionMore yearsLongitudinal trends in costs for palliative radiation for metastatic prostate cancer.
Robinson T, Dinan M, Li Y, Lee R, Reed S. Longitudinal trends in costs for palliative radiation for metastatic prostate cancer. Journal Of Clinical Oncology 2013, 31: 6554-6554. DOI: 10.1200/jco.2013.31.15_suppl.6554.Peer-Reviewed Original ResearchPalliative radiation therapyMetastatic prostate cancerProstate cancerRadiation therapyBony metastasesInclusion criteriaOutpatient facilitiesMedicare paymentsDistant metastatic diseaseTime of diagnosisPalliative radiation treatmentSEER-Medicare dataTreatment claimsStudy inclusion criteriaProstate cancer metastasisHealth care costsTotal Medicare paymentsAverage Medicare paymentsHealth care expendituresCarrier claimsPalliative radiationMetastatic diseasePalliative treatmentMedian ageMedian time
2011
Use of Patient-Reported Outcomes in Randomized, Double-Blind, Placebo-Controlled Clinical Trials
Dinan MA, Compton KL, Dhillon JK, Hammill BG, DeWitt EM, Weinfurt KP, Schulman KA. Use of Patient-Reported Outcomes in Randomized, Double-Blind, Placebo-Controlled Clinical Trials. Medical Care 2011, 49: 415-419. PMID: 21368680, PMCID: PMC3682647, DOI: 10.1097/mlr.0b013e3182064aa2.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesClinical trialsPRO instrumentsDisease-specific patient-reported outcomesDisease-specific PRO instrumentsMore PROsUse of PROsPrimary trial outcomeCurrent clinical trialsStudy inclusion criteriaUse of patientMultivariable analysisLarge trialsMajor therapeutic areasInclusion criteriaPRO measurementRelevant outcomesTrial outcomesLogistic regressionClinical researchStudy outcomesPRO outcomesTrialsTherapeutic areasStatistical significance